In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
A new analysis published in European Urology suggests that the risk window of recurrence for surgically treated renal cell carcinoma (RCC) may be longer than previously thought. Hoping…
Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
There have been many changes in the treatment landscape of stage II and stage III melanoma over the past decade. This article takes a look at the benefits…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA,…
A study conducted in Arizona by the Mayo Ciinic found reason to suspect that vaping is consistently associated with serious lung damage. Vaping causes a “severe chemical injury”…
The common carp, a fish species that is invasive in the US Midwest, may have finally met its match. Scientists with the Minnesota Aquatic Invasive Species Research Center…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Researchers at Villanova University in Philadelphia have constructed a model brain they say provides a noninvasive new way to study brain injury. A team of engineers led by…
Early data from the phase III CheckMate 067 trial, reported in September 2017, showed that patients with advanced melanoma treated with nivolumab, with or without ipilimumab, maintained their quality…
